Loading…
Evaluation of pneumococcal urinary antigen testing for respiratory tract infection investigations
•This study evaluated the use of pneumococcal urinary antigen testing for the diagnosis of lower respiratory tract infections, and identified factors associated with positive results to this test. To our knowledge this was the first study to assess the association between the pneumococcal urinary an...
Saved in:
Published in: | Médecine et maladies infectieuses 2020-02, Vol.50 (1), p.57-62 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •This study evaluated the use of pneumococcal urinary antigen testing for the diagnosis of lower respiratory tract infections, and identified factors associated with positive results to this test. To our knowledge this was the first study to assess the association between the pneumococcal urinary antigen test result and clinical, biological, and radiological data in real life. This study is a first step in the research for well-reasoned prescription of pneumococcal urinary antigen test to reduce prescriptions and cost.
The pneumococcal urinary antigen test enables rapid bacteriological diagnosis in respiratory tract infections. The objective was to identify factors associated with a positive pneumococcal urinary antigen test result.
This seven-year retrospective monocentric study was performed on consecutive patients presenting with respiratory tract infections reported as pneumococcal-positive. Epidemiological, biological, and radiological factors were analyzed, and severity scores were calculated.
A total of 223 patients were included. Significant associations were observed between positive test results and age over 65years (P=0.01), positive test results and immunosuppression factors (blood disease [25% Ag+ group vs. 4% Ag− group, P=0.001], immunosuppressive therapy [10% Ag+ group vs. 0% Ag− group, P=0.02]). Clinically, fever (64% Ag+ group vs. 42% Ag− group, P=0.01) and cough (46% Ag+ group vs. 19% Ag− group, P |
---|---|
ISSN: | 0399-077X 1769-6690 |
DOI: | 10.1016/j.medmal.2019.06.009 |